Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial

被引：1
|
作者：
Gradishar, W. J. [1 ]
Krasnojon, D. A. [2 ]
Cheporov, S. V. [3 ]
Makhson, A. N. [4 ]
Manikhas, G. M. [5 ]
Clawson, A. [6 ]
Bhar, P. [6 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[2] Leningrad Reg Oncol Ctr, Dept Chemotherapy, Kuzmolovo, Russia
[3] Yaroslavl Reg Clin Oncol Hosp, Dept Chemotherapy, Yaroslavl, Russia
[4] City Oncol Hosp 62, Dept Chemotherapy, Moscow, Russia
[5] St Petersburg City Oncol Ctr, Dept Chemotherapy, St Petersburg, Russia
[6] Celgene Corp, Biostat, Summit, NJ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71502-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [41] Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial
    Karthaus, Meinolf
    Poddubnaya, Irina
    Churilova, L.
    Khazanov, R.
    Veremeychuk, T.
    Rumyantzeva, E.
    Garin, M.
    Brichkova, O.
    Heinrich, Bernhard
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Loibl, Sibylle
    Schrader, Iris
    Huober, Jens
    Heilmann, Volker
    Beckmann, Matthias
    Staehler, Ann
    Jackisch, Christian
    Hubalek, Michael
    Richter, Barbara
    Stickeler, Elmar
    Eidtmann, Holger
    Thomssen, Christoph
    Untch, Michael
    Wollschlaeger, Kerstin
    Schuster, Tibor
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
  • [43] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans-Joachim Lück
    Andreas Du Bois
    Sibylle Loibl
    Iris Schrader
    Jens Huober
    Volker Heilmann
    Matthias Beckmann
    Ann Stähler
    Christian Jackisch
    Michael Hubalek
    Barbara Richter
    Elmar Stickeler
    Holger Eidtmann
    Christoph Thomssen
    Michael Untch
    Kerstin Wollschläger
    Tibor Schuster
    Gunter von Minckwitz
    Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
  • [44] Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer
    Stemmler, Hans-Joachim
    Harbeck, Nadia
    de Rivera, Isolde Groell
    Kaiser, Ursula Vehling
    Rauthe, Gerhard
    Abenhardt, Wolfgang
    Artmann, Almut
    Sommer, Harald
    Meerpohl, Hans-Gerd
    Kiechle, Marion
    Heinemann, Volker
    ONCOLOGY, 2010, 79 (3-4) : 197 - 203
  • [45] Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Syrigos, K.
    Kakolyris, S.
    Ziras, N.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2010, 21 (01) : 48 - 54
  • [46] Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France
    Pierga, Jean-Yves
    Delva, Remy
    Pivot, Xavier
    Espie, Marc
    Dalenc, Florence
    Serin, Daniel
    Veyret, Corinne
    Lortholary, Alain
    Gligorov, Joseph
    Joly, Katelle
    Hernandez, Juana
    Hardy-Bessard, Anne-Claire
    BULLETIN DU CANCER, 2014, 101 (09) : 780 - 788
  • [47] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
  • [48] Phase II Multicenter Study of Docetaxel and Bevacizumab (Bev) plus /- Trastuzumab as First-Line Treatment of Patients with Metastatic Breast Cancer (MBC)
    Schwartzberg, L. S.
    Hermann, R.
    Blakely, J.
    Richey, S. S.
    Tauer, K. W.
    Childs, B. H.
    CANCER RESEARCH, 2010, 70
  • [49] Sequential treatment with doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II GEICAM study
    Alba, E
    Antón, A
    Ribelles, N
    Pérez-Carrión, R
    López-Vega, J
    Llanos, M
    Pelegri, A
    Florián, J
    Menéndez, M
    Godés, M
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S66 - S66
  • [50] Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC)
    Guan, Z-z
    Xu, B-h
    Arpornwirat, W.
    Tong, Z-s
    Lorvidhaya, V.
    Wang, L.
    Newstat, B.
    DeSilvio, M.
    Moore, Y.
    Shen, Z-Z
    CANCER RESEARCH, 2010, 70
12345